Gelteq Limited focuses on developing, testing, and commercializing white label gel-based delivery solutions for humans and animals in Asia-Pacific Region. It offers edible gels for prescription drugs, nutraceuticals, pet care, and other products, as well as for sports and over-the-counter products. The company has a strategic alliance with IDT Australia Limited for the development and scale up of its gel-based products across diverse global pharmaceutical, nutraceutical and animal health markets and has a strategic alliance with Melbourne Health for the development of maize starch butyrylated, or HAMSB, a compound with the potential to reduce bowel polyp growth which could lower the risk of bowel cancer. Gelteq Limited was incorporated in 2017 and is headquartered in Caulfield, Australia.
Company profile updated October 12, 2026.
As of October 9, 2026. Daily closing data may differ from the live quote shown in the dashboard.
Compare the company’s price history and fundamentals in the dashboard. Explore disclosed trading and ownership activity in these research collections: